Celldex Therapeutics, Inc.
CLDX
$41.95
-$0.66-1.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 46.67% | -87.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 46.67% | -87.60% | |||
| Cost of Revenue | -7.48% | -3.10% | |||
| Gross Profit | 7.49% | 2.96% | |||
| SG&A Expenses | 14.45% | -4.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.51% | -3.24% | |||
| Operating Income | 4.51% | 3.12% | |||
| Income Before Tax | 6.59% | 3.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.59% | 3.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.59% | 3.24% | |||
| EBIT | 4.51% | 3.12% | |||
| EBITDA | 4.62% | 3.19% | |||
| EPS Basic | 20.12% | 3.34% | |||
| Normalized Basic EPS | 20.11% | 3.35% | |||
| EPS Diluted | 20.12% | 3.34% | |||
| Normalized Diluted EPS | 20.11% | 3.35% | |||
| Average Basic Shares Outstanding | 16.94% | 0.12% | |||
| Average Diluted Shares Outstanding | 16.94% | 0.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||